Riccardo Autorino, MD, PhD, FEBU, Author at Grand Rounds in Urology

Riccardo Autorino, MD, PhD, FEBU

Cleveland Clinic, Glickman Urological and Kidney Institute

Cleveland, Ohio

Riccardo Autorino, MD, PhD, FEBU, is the Director of Clinical Outcomes Research for the Glickman Urological and Kidney Institute at the Cleveland Clinic in Cleveland, Ohio.His main clinical interest is the minimally-invasive treatment of urologic cancers and benign urologic diseases using robotic-assisted surgery.

Dr. Autorino earned his medical degree and completed his residency in Urology at Federico II University in Napoli, Italy. He then earned his PhD in Urological Sciences and completed a secondary residency in Urology at Seconda Università in Napoli, Italy. Dr. Autorino then completed fellowships in Urology and Advanced Laparoscopic & Robotic Surgery at the Cleveland Clinic.

Dr. Autorino serves as a reviewer for numerous journals, and he serves as an editorial board member of European Urology, World Journal of Urology, Archivos Españoles de Urologia, and International Brazilian Journal of Urology. He is the Associate Editor for the Laparoscopy and Robotics section of Minerva Urologica e Nefrologica. He has co-authored over 300 peer-reviewed publications and several book chapters. Dr. Autorino has been awarded the Italian Matula Award by the Italian Society of Urology and the Hans Marberger Award at the annual EAU meeting.

Talks by Riccardo Autorino, MD, PhD, FEBU

AUA/ASTRO/SUO Guidelines on Clinically Localized Prostate Cancer

Riccardo Autorino, MD, PhD, FEBU | Jun 2018

Riccardo Autorino, MD, PhD, FEBU, summarizes the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) guidelines on clinically localized prostate cancer. Specifically, he highlights recommendations on shared decision making, risk stratification to dictate the therapy, care options, active surveillance, and directions for future research.

Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?

Riccardo Autorino, MD, PhD, FEBU | Jun 2018

Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.

Radical Prostatectomy for Oligometastatic Prostate Cancer: Is There Any Benefit?

Riccardo Autorino, MD, PhD, FEBU | May 2018

Riccardo Autorino, MD, PhD, FEBU, defines oligometastatic prostate cancer, a newly-explored concept in the urological community. He discusses whether or not radical prostatectomy offers significant oncological benefits that outweigh the risk of complications and negative impacts on urinary function and QOL outcomes for patients in this stage.

Nephron Sparing Surgery for Large Renal Tumors: Always, Sometimes, or Never?

Riccardo Autorino, MD, PhD, FEBU | May 2018

Riccardo Autorino, MD, PhD, FEBU, summarizes the current EAU, AUA, and ASCO recommendations regarding partial and radical nephrectomies, the effect robotic surgery has had in this clinical area, and whether or not nephron sparing surgery is a beneficial and safe method for the management of large renal masses.

Robotic Surgical Systems in Urology: What’s in the Pipeline?

Riccardo Autorino, MD, PhD, FEBU | May 2018

Riccardo Autorino, MD, PhD, FEBU, reviews the assets and limitations of the robotic systems currently available for clinical urological applications, especially the da Vinci system. He describes the global scene of emerging systems, such as the REVO-I and the avatera-System, as well as multiple systems under development.